Prostate cancer radiotherapy dose response: An update of the fox chase experience

被引:110
作者
Pollack, A
Hanlon, AL
Horwitz, EM
Feigenberg, SJ
Uzzo, RG
Hanks, GE
机构
[1] Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA
[2] Fox Chase Canc Ctr, Dept Biostat, Philadelphia, PA 19111 USA
[3] Fox Chase Canc Ctr, Dept Urol, Philadelphia, PA 19111 USA
关键词
prostate; prostatic neoplasms; radiotherapy; dose-response relationship; radiation;
D O I
10.1097/01.ju.0000111844.95024.74
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The effectiveness of increasing radiotherapy dose for men with prostate cancer was evaluated With reference to prognostic groups as defined by pretreatment serum prostate specific antigen (PSA), Gleason score, T stage and perineural invasion. Materials and Methods: There were 839 men treated between April 1989 and December 1997 with conformal radiotherapy alone. Cox multivariate analysis was used to establish important predictors of biochemical failure (BF) separately for patients with an initial pretreatment PSA (iPSA) of less than 10, 10 to 19.9, or 20 or greater ng/ml. Radiotherapy (RT) dose was evaluated as a continuous and categorical (dose groups of less than 72, 72 to 75.9 and 76 Gy or greater) variable. Results: At a median 63-month followup multivariate analysis demonstrated that iPSA and radiotherapy (RP) dose were the most significant predictors of BF, followed by Gleason score and T stage. Perineural invasion was not an independent correlate of outcome. RT dose was significant in all iPSA groups (less than 10, 10 to 19.9 and 20 or greater ng/ml). Gleason score was significant when iPSA was less than 10 ng/ml. T stage was significant when iPSA was 20 ng/ml or greater and it was borderline when iPSA was 10 to 19.9 ng/ml (p = 0.08). Prognostic subgroups were derived from these results and tested for an effect of RT dose on univariate analysis. Radiation dose was not a correlate of BF in the most favorable (PSA less than 10 ng/ml and Gleason score 2 to 6) and the most unfavorable (PSA 20 ng/ml or greater and stage T3-T4) prognostic groups but it was otherwise an influential determinant of outcome. Conclusions: RT dose escalation to 76 Gy or greater improved patient outcome for all prognostic groups except those at the favorable and unfavorable extremes.
引用
收藏
页码:1132 / 1136
页数:5
相关论文
共 22 条
[1]   Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA<10 ng/ml treated with conformal external beam radiation therapy [J].
Anderson, PR ;
Hanlon, AL ;
Patchefsky, A ;
Al-Saleem, T ;
Hanks, GE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (05) :1087-1092
[2]  
Bonin SR, 1997, CANCER-AM CANCER SOC, V79, P75, DOI 10.1002/(SICI)1097-0142(19970101)79:1<75::AID-CNCR11>3.0.CO
[3]  
2-3
[4]  
COX DR, 1972, J R STAT SOC B, V34, P187
[5]   TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) [J].
COX, JD ;
STETZ, J ;
PAJAK, TF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1341-1346
[6]  
Cox JD, 1997, INT J RADIAT ONCOL, V37, P1035
[7]   Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Blank, K ;
Broderick, GA ;
Tomaszewski, JE ;
Renshaw, AA ;
Kaplan, I ;
Beard, CJ ;
Wein, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974
[8]   Dose response in prostate cancer with 8-12 years' follow-up [J].
Hanks, GE ;
Hanlon, AL ;
Epstein, B ;
Horwitz, EM .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (02) :427-435
[9]   Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales [J].
Hanlon, AL ;
Schultheiss, TE ;
Hunt, MA ;
Movsas, B ;
Peter, RS ;
Hanks, GE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 38 (01) :59-63
[10]  
Horwitz EM, 2001, CANCER, V92, P1281, DOI 10.1002/1097-0142(20010901)92:5<1281::AID-CNCR1449>3.0.CO